Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.35 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840217 | 0.83 | RXRA (0.51) | RXRAFGFR1THRBKDM4EHPGD | |
| SCHEMBL6840261 | 0.81 | LMNA (0.46) | RXRAMGLLMRGPRX4TEAD1TEAD4 | |
| SCHEMBL6840214 | 0.81 | MAPT (0.49) | MRGPRX4KDM4EGLAHPGD | |
| SCHEMBL122436 | 0.77 | MGLL (0.57) | RXRAMGLLTEAD1TEAD4TEAD2 | |
| SCHEMBL6840252 | 0.74 | TTR (0.52) | RXRAMGLLMRGPRX4RXRBRXRG | |
| SCHEMBL6840215 | 0.74 | SCN2B (0.43) | RXRAMGLLMRGPRX4FGFR1THRB | |
| SCHEMBL6840238 | 0.74 | RXRA (0.44) | RXRAMGLLFGFR1THRBKDM4E | |
| SCHEMBL6840192 | 0.73 | ROCK2 (0.53) | MGLLHPGD | |
| SCHEMBL6840177 | 0.72 | RXRA (0.43) | RXRAMGLLTHRBKDM4EHPGD | |
| SCHEMBL121755 | 0.72 | MGLL (0.56) | RXRAMGLLTHRBKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| US-8722658-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8623858-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-07 | — | — | US | disclosed |
| EP-2421825-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-01 | — | — | EP | disclosed |
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-08-22 | — | — | US | disclosed |
| US-8513423-B2 | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124119-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124114-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124102-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324011-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885MGLL 5/4885MRGPRX4 330/4885 |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885MGLL 5/4885MRGPRX4 330/4885 |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885MGLL 5/4885MRGPRX4 330/4885 |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885MGLL 5/4885MRGPRX4 330/4885 |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885MGLL 5/4885MRGPRX4 330/4885 |
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | RXRA 2126/4885MGLL 1/4885MRGPRX4 467/4885 |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885MGLL 5/4885MRGPRX4 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.